Faculty Opinions recommendation of Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.

2013 ◽  
Author(s):  
Ashish Kamat ◽  
Daniel Levi Willis
Keyword(s):  
Prospective Study ◽  
Tumor Cells ◽  
Radical Cystectomy ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Her2 Expression ◽  
Prognostic Role ◽  
A Prospective Study

Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 11043-11043 ◽  
Author(s):  
Julia Katharina Neugebauer ◽  
Brigitte Kathrin Rack ◽  
Bernadette Anna Sophia Jaeger ◽  
Ulrich Andergassen ◽  
Aurelia Pestka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Her2 Status ◽  
Her2 Overexpression ◽  
Her2 Expression ◽  
Her2 Positive ◽  
Before And After

11043 Background: The discordance between HER2-expression on circulating tumor cells (CTC) in peripheral blood and the primary tumor has already been shown by our study group for early breast cancer patients with HER2-positive tumors. Here, we compare the results to CTC prevalence and HER2-status of CTC after adjuvant chemotherapy. Methods: The SUCCESS B trial compares FEC-Docetaxel vs. FEC-Docetaxel-Gemcitabine and HER2-targeted therapy as adjuvant treatment for patients with early, HER2-positive, node positive or high risk node negative primary breast cancer. We prospectively analyzed 23ml peripheral blood before and after chemotherapy. CTC and HER2-status were assessed with the CellSearchSystem (Veridex, USA). After immunomagnetic enrichment with an anti-Epcam-antibody, cells were labeled with anti-CK 8/18/19, anti-CD45 antibodies as well as a fluorescein conjugate antibody for HER2-phenotyping. Cutoff for CTC positivity was ≥ 1 CTC. HER-positivity of CTC was assigned if at least one CTC showed strong HER2 staining (3+). Results: CTCs and their HER2-status both before and after chemotherapy were available for 392 patients. In 179 (45.7%) patients no CTC were detected before and after chemotherapy. CTC status changed from positive before to negative after chemotherapy in 104 (26.5%) patients and from negative before to positive after chemotherapy in 69 (17.6%) patients, while 40 (10.2%) patients had a consistently positive CTC status. Patients were significantly more likely to change their CTC status from positive to negative than from negative to positive (p = 0.01). Of the 40 patients with CTC both before and after chemotherapy, 14 (35%) patients had HER2-positive CTC before and after therapy, and 9 (22%) patients had HER2-negative CTC at both time points. 7 (18%) patients had HER2-positive CTC before but not after chemotherapy, while 10 (25%) patients showed the reverse pattern (p = 0.63). Conclusions: Cytotoxic treatment does not seem to influence the HER2-status on CTC. Follow-up data within the Success B trial will analyze the relevance of the HER2-expression of CTC to predict the efficacy of targeted treatment.

scholarly journals Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study

Oncotarget ◽  
2016 ◽  
Vol 7 (24) ◽  
pp. 36645-36654 ◽  
Author(s):  
Qiang Li ◽  
Xiaofei Zhi ◽  
Jianping Zhou ◽  
Ran Tao ◽  
Jiaxuan Zhang ◽  
...  
Keyword(s):  
Prospective Study ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Gastrointestinal Stromal Tumors ◽  
Predictive Marker ◽  
Stromal Tumors ◽  
A Prospective Study

scholarly journals Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study

PLoS ONE ◽  
2019 ◽  
Vol 14 (5) ◽  
pp. e0217586 ◽  
Author(s):  
Michinori Hamaoka ◽  
Tsuyoshi Kobayashi ◽  
Yuka Tanaka ◽  
Hiroaki Mashima ◽  
Hideki Ohdan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prospective Study ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Significance ◽  
A Prospective Study

The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study

2020 ◽  
Vol 47 (12) ◽  
pp. 9645-9657
Author(s):  
Abeer A. Bahnassy ◽  
Yasser A. Abdel-Azim ◽  
Somaya Ezzat ◽  
Mona S. Abdellateif ◽  
Abdel-Rahman N. Zekri ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Prospective Study ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Ras Mutations ◽  
A Prospective Study

scholarly journals Circulating Tumor Cells in Desmoid Tumors: New Perspectives

2021 ◽  
Vol 11 ◽  
Author(s):  
Alexcia C. Braun ◽  
Fernando A. B. Campos ◽  
Emne A. Abdallah ◽  
Anna P. C. Ruano ◽  
Tiago da S. Medina ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Transforming Growth Factor ◽  
Growth Factor Receptor ◽  
Recurrence Rates ◽  
Primary Tumors ◽  
Cox 2 ◽  
A Prospective Study ◽  
And Behavior

IntroductionDesmoid tumor (DT) is a rare neoplasm with high local recurrence rates, composed of fibroblastic cells that are characterized by the expression of key molecules, including the intermediate filament vimentin, cyclooxygenase-2 (COX-2), and nuclear β-catenin, and lack of epithelial markers. Circulating tumor cells (CTCs) isolated from the peripheral blood of patients with sarcomas and other neoplasms can be used as early biomarkers of tumor invasion and dissemination. Moreover, CTCs can also re-colonize their tumors of origin through a process of “tumor self-seeding.”ObjectivesWe aimed to identify CTCs in the peripheral blood of patients with DT and evaluate their expression of β-catenin, transforming growth factor receptor I (TGF-βRI), COX-2, and vimentin proteins.Material and MethodsWe conducted a prospective study of patients with initial diagnosis or relapsed DT with measurable disease. Blood samples from each patient were processed and filtered by ISET® (Rarecells, France) for CTC isolation and quantification. The CTC expression of β-catenin, COX-2, TGF-βRI, and vimentin was analyzed by immunocytochemistry (ICC).ResultsA total of 18 patients were included, and all had detectable CTCs. We found a concordance of β-catenin expression in both CTCs and primary tumors in 42.8% (6/14) of cases by using ICC and immunohistochemistry, respectively.ConclusionsOur study identified a high prevalence of CTCs in DT patients. Concordance of β-catenin expression between primary tumor and CTCs brings new perspectives to assess the dynamics of CTCs in the blood compartment, opening new avenues for studying the biology and behavior of DT. In addition, these results open the possibility of using CTCs to predict DT dynamics at the time of disease progression and treatment. Further studies with larger sample sizes are needed to validate our findings.

Sign in / Sign up

Export Citation Format

Share Document